Viatris' all-cash offer of $36.50 per share for pain-drug maker Pacira Biosciences is built to close quickly, and analysts at RBC Capital Markets believe that structure leaves little room—or time—for a rival bidder to step in.
The deal, announced earlier this month, values Pacira at about $1.65 billion. RBC's assessment, shared in a note to clients, highlights several features of the merger agreement that make a competing offer difficult to pull off.
Why a rival bid is unlikely
RBC points to the merger agreement's "no-shop" clause, which restricts Pacira from actively soliciting other buyers. While Pacira can still respond to an unsolicited proposal, the deck is stacked against any interloper.
The timeline is unusually tight. RBC expects Viatris to launch a tender offer within 15 business days and keep it open for an initial 10 business days. That gives Viatris just four business days to match any superior bid that might emerge. For a potential rival, that's a very short window to conduct due diligence, line up financing, and make a credible counteroffer.
Adding to the hurdle is a $62 million breakup fee. If Pacira walks away for a better offer, it would have to pay that fee to Viatris—a cost that would eat into any premium a rival might offer. Pacira's board has already unanimously backed the deal, which further reduces the odds of a competing bid.
The offer itself also carries a hefty 45% premium over Pacira's share price before the announcement. And because it's all cash and doesn't depend on securing financing, there's less risk of the deal falling through due to funding issues.
What the spread tells us
Pacira's shares are trading at about $36.31, just 19 cents below the $36.50 offer price. In merger deals, that gap—known as the "spread"—is the market's way of pricing in the risks and the time it might take to close. A narrow spread usually signals that investors expect the deal to go through smoothly and soon.
RBC's view is that the compressed tender window makes it hard for another bidder to move fast enough. The short match period means any rival would have to act almost immediately, which is a tall order in a complex acquisition. That's why day-to-day moves in Pacira's stock are likely to be driven less by hopes for a higher offer and more by residual closing risks, such as the ongoing litigation over Pacira's key product, Exparel.
RBC has lifted its price target on Pacira to the offer price, reflecting its expectation that the deal will close at that level.
What it means for investors
For investors holding Pacira shares, the message is fairly straightforward: the deal looks likely to close at $36.50, and the upside from here is limited. The 19-cent spread represents the market's assessment of the remaining risks, including the Exparel lawsuit and the possibility of a regulatory hiccup.
For those watching from the sidelines, the structure of this deal is a reminder of how merger agreements can be designed to discourage competing offers. The combination of a no-shop clause, a tight timeline, and a breakup fee creates significant barriers for any rival bidder.
It's also worth noting that Viatris, a global healthcare company, is making a strategic bet on Pacira's non-opioid pain management portfolio, which includes Exparel. The litigation over Exparel is a lingering overhang, but RBC's analysis suggests it's not enough to derail the deal.
For a broader look at how merger deals can play out, you might find our coverage of the original Viatris-Pacira announcement helpful. And for context on how market conditions can affect deal-making, our piece on oil prices and a major asset sale shows how external factors can shift the landscape.
Ultimately, the takeaway for everyday investors is that this deal appears to be on track. The tight structure means the outcome is likely to be a quick close at the offered price, rather than a bidding war. As always, it's wise to keep an eye on any developments in the Exparel litigation, but the current setup suggests the deal will proceed as planned.
